Literature DB >> 27847018

More than half of presumptive multidrug-resistant cases referred to a tuberculosis referral laboratory in the Tigray region of Ethiopia are multidrug resistant.

Kebede Tesfay1, Shinesh Tesfay2, Etsay Nigus3, Araya Gebreyesus1, Dawit Gebreegziabiher1, Kelemework Adane4.   

Abstract

OBJECTIVE/
BACKGROUND: Generating epidemiological data on multidrug-resistant tuberculosis (MDR-TB) is essential to assess the magnitude and trends of anti-TB drug resistance. This study determined the prevalence of MDR-TB among presumptive MDR cases referred to a TB referral laboratory in the Tigray region of Ethiopia.
METHODS: A retrospective cross-sectional study was conducted on 262 culture-positive presumptive MDR-TB samples submitted to the Tigray Regional Research Laboratory for MDR testing between January 2013 and August 2014. Relevant data were recorded using a structured recording format.
RESULTS: Out of 262 Mycobacterium tuberculosis isolates, 143 (54.6%) were MDR, 28 (10.7%) were resistant to rifampicin only, and 19 (7.3%) were resistant to isoniazid only. The prevalence of MDR-TB among newly infected cases was 66.7% (8/12) and that among previously treated cases was 54.1% (97/179). Of the variables tested, being a male was found to be associated with the development of MDR-TB (p=.003).
CONCLUSION: More than half of the presumptive MDR cases referred to the Tigray Regional Research Laboratory were MDR. The prevalence was high in both newly infected and previously treated cases. Hence, re-enforcing the TB prevention methods, and strengthening the directly observed treatment short-course (DOTS) strategy and the capacity of laboratories to undertake drug susceptibility testing (DST) in the region are imperative in order to curb the emergence and transmission of MDR-TB.
Copyright © 2016 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ethiopia; Multidrug-resistant tuberculosis; Previously treated

Mesh:

Year:  2016        PMID: 27847018     DOI: 10.1016/j.ijmyco.2016.07.007

Source DB:  PubMed          Journal:  Int J Mycobacteriol        ISSN: 2212-5531


  8 in total

1.  Spatial patterns of multidrug resistant tuberculosis and relationships to socio-economic, demographic and household factors in northwest Ethiopia.

Authors:  Kefyalew Addis Alene; Kerri Viney; Emma S McBryde; Archie C A Clements
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

2.  Tuberculosis treatment outcome and predictors in northern Ethiopian prisons: a five-year retrospective analysis.

Authors:  Kelemework Adane; Mark Spigt; Geert-Jan Dinant
Journal:  BMC Pulm Med       Date:  2018-02-20       Impact factor: 3.317

3.  Tuberculosis patients are physically challenged and socially isolated: A mixed methods case-control study of Health Related Quality of Life in Eastern Ethiopia.

Authors:  Aklilu Abrham Roba; Tamirat Tesfaye Dasa; Fitsum Weldegebreal; Abyot Asfaw; Habtamu Mitiku; Zelalem Teklemariam; Mahantash Naganuri; Bahubali Jinnappa Geddugol; Frehiwot Mesfin; Hilina Befikadu; Eden Tesfaye
Journal:  PLoS One       Date:  2018-10-15       Impact factor: 3.240

4.  The Magnitude of MTB and Rifampicin Resistance MTB Using Xpert-MTB/RIF Assay Among Tuberculosis Suspected Patients in Gedeo Zone, Southern Ethiopia.

Authors:  Kuma Diriba; Ephrem Awulachew; Gemechu Churiso
Journal:  Infect Drug Resist       Date:  2021-09-24       Impact factor: 4.003

5.  Proportion and trend of primary resistance among Multidrug resistant Tuberculosis patients in Ethiopia.

Authors:  Adamu Bayissa; Meaza Demissie; Mulatu Biru; Zenebe Akalu
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-04-25

6.  Treatment Interruption Among Drug-Susceptible Pulmonary Tuberculosis Patients in Southern Ethiopia.

Authors:  Moges Getie Workie; Moges Wubie Aycheh; Molla Yigzaw Birhanu; Tesfa Birlew Tsegaye
Journal:  Patient Prefer Adherence       Date:  2021-05-26       Impact factor: 2.711

7.  Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.

Authors:  Tsegahun Manyazewal; Yimtubezinash Woldeamanuel; David P Holland; Abebaw Fekadu; Henry M Blumberg; Vincent C Marconi
Journal:  Trials       Date:  2020-05-05       Impact factor: 2.279

8.  Frequency of MTB and rifampicin resistance MTB using Xpert-MTB/RIF assay among adult presumptive tuberculosis patients in Tigray, Northern Ethiopia: A cross sectional study.

Authors:  Araya Gebreyesus Wasihun; Tsehaye Asmelash Dejene; Genet Gebrehiwet Hailu
Journal:  PLoS One       Date:  2020-11-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.